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ABSTRACT
Known since the 19th century, neuromyelitis optica (NMO), or Devic’s disease, 
is an idiopathic immune-mediated inflammatory demyelinating disease of the 
central nervous system selectively affecting the optic nerve and spinal cord. 
Commonly diagnosed in demyelinating diseases reference centers, we report 
an 18-year-old female patient who sought medical attention with a 3-month 
history of weight loss, headache, and vomiting, followed by diplopia, a burning 
sensation over the lower limbs, and difficulty walking. A few days prior to 
hospital admission, the muscle strength in her lower limbs became worse and 
ascended to the upper limbs associated with sensory changes in the trunk and 
voiding dysfunction. At admission, the neurological examination was consistent 
with a spinal cord syndrome. After few days of hospitalization, she was 
tetraplegic with severe signs of brainstem involvement requiring mechanical 
ventilatory support. Intravenous methylprednisolone and cyclophosphamide 
were promptly started after ruling out the diagnosis of infectious disease and 
cord compression. Due to no substantial early improvement, intravenous 
immunoglobulin was also used. From then on, the neurological status gradually 
improved. Magnetic resonance imaging showed extensive demyelinating 
features in the spinal cord, and the serum IgG autoantibody was negative. 
The patient was referred to a tertiary neurological reference center where she 
remains under treatment.
Keywords: Neuromyelitis Optica; Demyelinating Diseases; Respiratory Insufficiency; Magnetic 
Resonance Imaging; Pulse Therapy; Drug.
CASE REPORT
A previously healthy, 18-year-old female 
patient of African descent sought medical care with 
a history of weight loss of 14 kg during the last 3 
months simultaneously with headache and vomiting. 
Two weeks after the onset of the symptoms, she 
started with diplopia and a burning sensation 
over the lower limbs that lasted for a month and 
progressed to face and scalp allodynia. She also 
had gait instability. A few days before hospital 
admission, the muscle strength of her lower limbs 
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resonance imaging (MRI) was not performed initially 
due to clinical instability and because transport to 
another institution was considered life threatening.
Based on the clinical prodrome (weight 
loss, vomiting, headache with unknown origin), 
neurological presentation (transverse myelitis, 
quickly progressing to brainstem dysfunction), 
compressive cord lesion dismessed by tomographic 
study, CSF inflammatory abnormalities, and 
negative workup to more common infectious 
agents, the diagnosis of neuromyelitis optica 
(NMO) was highly considered. Pulse therapy with 
methylprednisolone (1g/day for 5 days), in addition 
to cyclophosphamide (1 g), was started as soon 
as her neurological status became worse. After 1 
week of pulse therapy, her neurological impairment 
remained unchanged, except for muscle strength 
grade 3 at wrist extension in both hands. Therefore, 
intravenous immune globulin (400 mg/kg/day for 
5 days) was also prescribed. Prednisone 40 mg/
day was continued until the next pulse. From that 
time, her neurological deficits started to gradually 
improve. She received one more pulse before the 
hospital discharge. She was discharged without 
tracheostomy with normal ventilatory parameters, 
and independent for eating after 40 days of 
hospitalization. She was unable to walk, but was 
able to remain seated without aid. The muscle 
strength was grade 4 with distal predominance in 
the upper limbs, and was grade 3 proximal and 
grade 2 distal in the lower limbs. The deep tendon 
reflexes persisted as brisk in the lower limbs, and 
hypoactive in the upper limbs, but a brisk finger 
flexor response was obtained when bicipital reflex 
was searched in the left side. She also complained 
of visual blurring at the left eye with normal acuity, 
although a slightly pale optic disk was detected, and 
the vertical nystagmus was persistent. The sensory 
deficit remained at T2 level; however, there was 
an improvement of the vibratory perception at the 
knees. She regained the voiding control.
Despite an MRI having been done 20 days 
after immunosuppressive treatment, areas of signal 
alteration in the brain stem, optic nerve and tract, 
left thalamus and basal ganglia with demyelinating 
features were found at brain imaging study (Figure 1 
and 2)
Diffuse signal alteration throughout the 
cervical and thoracic segment, characterized by 
elongated hyperintense areas on T2-weighted and 
FLAIR images, was observed. These areas were 
predominantly located at the periphery of the cervical 
became impaired and ascended to the upper limbs. 
This was associated with sensory changes in the 
trunk and urinary incontinence.
Initial examination showed an ill-looking 
patient with preserved cognitive functions, 
emaciated, pale, acyanotic, and with stable 
hemodynamic parameters. She denied dyspnea. 
Neurological examination showed slight asymmetric 
tetra paresis with muscular strength of grade 0 in the 
lower right limb and grade 3 in the upper right limb, 
and grade 1 in the lower left limb and grade 3 in the 
upper left limb. Deep tendon reflexes were absent in 
the upper limbs but were brisk with extensor plantar 
response in the lower limbs. All sensory modalities 
were compromised in limbs and trunk at T2 level. 
Cranial nerves were normal. Catheterization was 
necessary due to voiding dysfunction.
Initial laboratory workup included ANA and 
other inflammatory markers; serology for hepatitis 
B and C, HIV, HTLV, and syphilis showed negative 
results; blood and urine cultures were also negative. 
The lumbar cerebral spinal fluid (CSF) analysis 
disclosed slight inflammatory changes (Table 1) with 
negative results for China ink and cultures (aerobic, 
fungal, and acid fast bacilli). The brain and spine 
computed tomographies were normal.
After 3 days in hospital, she rapidly 
evolved with plegia in all limbs, nasal voice and 
swallowing disturbances with preserved bulbar 
reflexes, vertical nystagmus, bilateral internuclear 
ophthalmoparesis, and acute respiratory failure that 
required mechanical ventilatory support. Magnetic 
Table 1 – Lumbar cerebrospinal fluid analysis
Parameter Result Reference value
White blood count cell/mm3
Lymphocytes %
Monocytes %
Neutrophils %
11
93
7
0
1-4
50-70
30-50
< 2
Protein mg/dL
Prealbumin %
Albumin %
α-1 Globulin %
α-2 Globulin %
β Globulin %
δ Globulin %
γ Globulin %
63
1.7
70.8
2.5
5.8
10.4
1.7
10.0
15-40
3.0-7.0
45-70
3.0-7.0
5.0-11.0
7.0-13.0
4.0-10.0
5.0-14.0
Glucose mg/dL 60 2/3 glycemia
Adenosine deaminase U/L 1.23 <4.0
Lactate mg/dL 17.6 10-20
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Historically, the first three cases were 
reported by Portal in 1804, Pescetto in 1844, and 
Clarke in 1865.3 The first association between 
myelitis and optic disorder was mentioned by Allbutt 
in 1870. In 1882, Dreschfeld first suggested that 
the combination of myelitis and optic neuritis was 
a clinical syndrome. Devic defined the clinical entity 
“neuromyélite optique” in 1894, and since then this 
condition has been called Devic’s disease.1,4 Several 
cases and series reports have been published and 
various diagnostic criteria have been proposed since 
then. Initially considered as a subtype or clinical 
variant of multiple sclerosis for many decades, NMO 
had its own clinical identity, which was defined in 
2004 after the discovery of the specific autoantibody 
(IgG-NMO) whose antigen aquaporin-4 (AQP4) was 
characterized 1 year later.5,6
After the broad clinical NMO definition 
proposed by Gault and Devic, several diagnostic 
level, and centrally located at mid-thoracic level with 
small areas of vanished gadolinium enhancement. 
These alterations were continuous and confluent 
with slight expanding effect (Figure 3).
Tested in a frozen (−20ºC) stored sample, 
serum IgG-NMO was negative.
DISCUSSION
Devic’s disease or NMO is an idiopathic 
immune-mediated inflammatory demyelinating 
disease of the central nervous system (CNS) that 
selectively affects the optic nerve and spinal cord.1,2 
Partial or complete, unilateral or bilateral, visual loss 
represents optic nerve impairment, while para- or 
tetraplegia or paresis, sensory loss, and sphincter 
dysfunction exemplify spinal cord involvement.
Figure 2 – Coronal MRI images of the Brain weighted in T1 gadolinium injection, showing thickness and 
contrast enhancement in left optic nerve (A) and tract (B).
Figure 1 – Axial MRI images of the Brain weighted in T2 showing slight hyperintense areas in the brainstem 
(pons) (A), periaqueductal (B), and basal ganglia (C) with demyelinating features.
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Commonly, the initial presentation of NMO 
can be visual loss (in 45% of patients) or myelopathy 
(38%) that usually appear 3 months apart in most 
cases. The simultaneous involvement of the spinal 
cord and optic nerve, as was observed in this case 
report, can occur in 17%.4,10 A prodrome of fever, 
myalgia, sore throat or headache is present in around 
one-third of cases. In pediatrics, NMO is preceded 
by infection in 72% of patients. After the inaugural 
neurological event, the clinical course may be either 
monophasic, with no further events, or relapsing 
with additional attacks of myelitis, optic neuritis or 
both.1,4 Relapsing NMO is twice as frequent than the 
criteria appeared in the literature and some of them 
are presented in Table 2.7-11 They could roughly be 
divided into three periods: the first period may be 
coined as the pre-MRI era in which the diagnosis 
was only based on clinical findings of spinal cord 
and/or optic nerve lesion at the same time that other 
diseases that shared similar neurological symptoms 
and signs were ruled out. The second period is 
characterized by the inclusion of MRI abnormalities, 
and the third period was defined by serum IgG-
NMO status. Nowadays there is a growing trend to 
expand the NMO clinical spectrum.12
Figure 3 – Sagittal MRI images, (A) of the cervical spine weighted in T2 showing peripheral lesions (arrows), 
while those of thoracic spine are centrally distributed in (C) (arrows). (B) - sagittal T1 MRI image of the 
cervical spine after gadolinium injection showing slight enhancement of lesions (arrow). Axial T2 MRI images 
of de cervical (D) and thoracic (E) spines show hyperintense intramedullary lesions (arrows).
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monophasic NMO. The severity of disease onset 
ranges from fulminant and fatal (around one-third) 
to recovery with varying degrees of disability. In 
pediatrics generally, the outcome is favorable with 
complete neurological recovery.4
monophasic type and commonly associated with 
the female gender, older age onset, less severe 
motor impairment in the first myelitis attack, and 
the presence of systemic autoimmunity.1,4,10 The 
neurological impairment is usually more severe in 
Table 2 – Diagnostic criteria of neuromyelitis optica
Year Author(s) Criteria
1894 Gaut and Devic1,3 Retrobulbar neuritis or papilitis + acute myelitis
With/without other symptoms or signs not restricted to the spinal cord or 
optic nerve
1981 Shibasaki et al.6 Acute bilateral visual impairment and transverse myelitis occurring succes-
sively <4 weeks following a monophasic course
1993 Mandler et al.7 Clinical
1. Acute lesion of spinal cord and nerve optic, coincidental or separated 
by months or years
2. Without brainstem, cerebellar or cortical features
Imaging
1. Enlargement and cavitation on spinal cord MRI
2. Normal-appearing brain MRI
CFS
1. Decreased serum/CFS albumin ratio
2. Normal IgG synthesis
3. Usually absence of oligoclonal bands
Pathology
1. Spinal cord necrosis and cavitation, thickened vessel walls, absence of 
inflammatory infliltrates
2. Demyelination of optic nerve with or without cavitation
3. No demyelinating lesions in brain, brainstem, or cerebellum
1996 O’Riordan et al.8 1. Complete transverse myelitis evolving over 1–14 days, with sensory level 
and in the absence of cord compression
2. Acute unilateral or bilateral optic neuropathy
3. No clinical involvement beyond the spinal cord or optic nerves
4. The disease can be monophasic or multiphasic
1999 Wingerchuk et al.9 All absolute criteria + one major supportive criterion or two minor supportive 
criteria
Absolute criteria
1. Optic neuritis
2. Acute myelitis
3. No evidence of clinical disease outside of the optic nerve or spinal cord
Major supportive criteria
1. Negative brain MRI at onset
2. Spinal cord MRI lesion extending over > 3 vertebral segments
3. CFS pleocytosis of > 50 WBC/mm3 or > 5 neutrophils/mm3
Minor supportive criteria
1. Bilateral optic neuritis
2. Severe optic neuritis with fixed visual acuity worse than 20/200 in at 
least one eye
3. Severe, fixed, attack-related weakness (MRC grade < 2) in one or more 
limbs
2006 Wingerchuk et al.10 Revised criteria for definite NMO
Optic neuritis
Acute myelitis
At least two of three supportive criteria
1. Contiguous spinal cord lesion extending over > 3 vertebral segments
2. Bran MRI not meeting diagnostic criteria for multiple sclerosis
3. NMO-seropositive status
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NMO has been associated with other 
autoimmune diseases, which are a part of large 
differential diagnosis presented in Table 3. 
Antinuclear antibodies (ANA), anti-SSA, anti-
SSB, anti-cardiolipin, perinuclear antineutrophil 
cytoplasmatic (ANCA), anti-thyroid peroxidase are 
some examples of circulating autoantibodies that 
can occur without their associated systemic clinical 
condition.1
Regardless of differences in the data 
collection and diagnostic criteria, several authors 
have reported that NMO is more prevalent in 
areas with Black, Asian, and Indian populations.1,13 
For example, in North American and European 
countries, NMO constitutes less than 1% of CNS 
demyelinating diseases while it accounts for 
98% and 17.3% in Nigerian and French African-
Caribbean nationalities, respectively.4,14,15 Few 
Brazilian studies disclosed 11% of Devic’s disease 
diagnosed among African descendants.16,17 Women 
are overrepresented in all NMO series; for instance, 
9:1 in China, 5:1 in Brazil, and 9:1 in Martinique. In 
the USA, rates of 1:1 in monophasic NMO and 5:1 
in recurrent NMO are shown.1 The median age of 
In the case of this report, the earliest 
symptoms were vomiting, weight loss, and headache. 
Currently, it is well known that approximately 15% of 
NMO patients have symptoms and signs indicating 
disease outside the optic nerve and spinal cord, 
which can antedate or occur during the course of 
the disease.1,10,12 Some of these cases could be 
justified by high expression of AQP4 and consequent 
susceptibility to immune attack by the antibody 
anti-AQP4. For instance, intractable hiccups, 
nausea, and vomiting are the most common brain 
symptoms in NMO due to involvement of the area 
postrema. In addition, hypothalamic lesions could 
explain anorexia and weigh loss, hyperphagia 
and obesity, hypothermia, fever, syndrome of 
inappropriate secretion of antidiuretic hormone and 
other endocrine dysfunction, diffuse anhydrose, 
bradycardia, hypotension, and recurring episodes of 
coma. Confusion, decreased consciousness, coma, 
ocular movement disturbances, retrochiasmal 
visual field defects, cortical blindness, seizures, 
and aphasia could be present as encephalopathic 
manifestations.
Table 3 – More common differential diagnosis in NMO syndrome
Systemic immune-mediated inflammatory diseases Systemic lupus erytemathosus
Sjögren syndrome
Mixed connective tissue disease
Antiphospholipid antibody syndrome
Sarcoidosis
Paraneoplastic syndrome
Infections
Viral Cytomegalovirus
Varicella-zoster virus
Epstein-Barr virus
Human immunodeficiency virus
Bacterial Syphilis
Tuberculosis
Borreliosis
Parasites Schistosoma mansonii
Toxocara spp
Toxicity Methanol
Ethylene glycol
Ethambutol
Clioquinol
Chemotherapeutic agents
Radiation
Nutritional deficiency Vitamin B12
Idiopathic central nervous system demyelinating diseases Multiple sclerosis
Neuromyelitis optica
Acute disseminated encephalomyelitis
Idiopathic optic neuritis
Neoplasia Lymphoma
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was suggested that pathological lesion occurred 
in stages with perivascular inflammation being 
the earliest.22 As recently demonstrated in an 
autopsy series, immunoglobulin deposition, 
activated complement, eosinophils, and myelin 
protein reactive macrophages were found in the 
perivascular space of spinal cord blood vessels 
suggesting that this space was the target for humoral 
autoimmune attack.23 This research culminated in 
the identification of IgG-NMO that binds to AQP4 in 
the abluminal face of cerebral microvessels which 
correspond to astrocytic foot processes.5,6
Aquaporins encompass a family of water 
channels, which control the water transport in 
several organs. AQP4 is the most abundant 
aquaporin in the mammalian brain (astrocytes and 
ependymal cells) and its loss may result both in 
severe damage of myelin and axons in vulnerable 
areas in which it is overexpressed (spinal cord, 
optic nerves, hypothalamus, and periventricular 
and periaqueductal structures).24,25 Although useful 
for diagnostic purposes, IgG-NMO titer has no 
correlations with disease duration, the number of 
relapses, or the effects of immunotherapies.1 In 
addition, there is no definite evidence that anti-AQP4 
antibody causes NMO because its administration 
to experimental models does not reproduce the 
disease and AQP4-knockout mice do not express 
the NMO phenotype. Also, other questions remain 
unanswered, such as the predominance of spinal 
cord and optic nerve lesions, while AQP-4 is 
ubiquitously expressed throughout – not only in 
CNS, but also in kidneys, lungs, inner ear, and 
intestine. Lastly, one could ask, what trigger event 
opens the blood-brain barrier?
NMO treatment starts with high-dose 
intravenous methylprednisolone (1 g/day for 5 
consecutive days).1 In cases of corticotherapy 
resistance, plasma exchange therapy is helpful 
but does not prevent further relapses.10,26 
Lymphocytapheresis could be used in bilateral blinded 
and tetraplegic patients who were unresponsive 
to high-dose intravenous corticosteroid and 
plasma exchange or intravenous immunoglobulin 
treatment.27 This therapeutic protocol is also applied 
to recurrent attacks. Early prophylactic treatment 
is recommended, mainly in IgG-NMO-positive 
patients, to avoid future relapses.1 From anecdotal 
published experiences in NMO treatment, each 
service designed its own drug protocol, generally 
based on immunosuppressive drugs (azathioprine, 
cyclophosphamide, methotrexate, mitoxantrone, 
mycophenolate mofetil).28-31 More recently, rituximab 
symptoms onset ranges from 40 years in relapsing 
NMO and 29 years in the monophasic type. The 
median age in pediatrics was 4.4 years.1,4,18
Since the phenotype of NMO can be shared 
with several diseases in which optic neuritis and 
myelitis are present isolated or simultaneously, the 
differential diagnoses are very broad and should be 
carefully explored (Table 3).
An ally to cardinal neurological symptoms 
and signs, MRI is one of the most important 
auxiliary exams for NMO diagnosis. As observed 
in the case reported here, the spinal cord study 
shows longitudinally extensive areas of increased 
signal intensity on T2-weighted and FLAIR images 
(demyelinating features) extending through several 
vertebral segments, with varying degrees of 
gadolinium enhancement on T1-weighted images, 
and, in the acute phase, a marked swelling of the cord 
could simulate a tumorigenic lesion.12,19 A cavity is 
seen in cases with severe disease, and cord atrophy 
appears in late stages. Brain MRI may be normal 
or show nonspecific changes; when white matter 
abnormalities are present, they are considered “not 
typical for multiple sclerosis” or, characteristically, 
are found in areas with high expression of AQP4 
(hypothalamus, areas surrounding the third and 
fourth ventricles).20 The optic nerve can show the 
same demyelinating features.
Another diagnostic auxiliary exam is CFS 
analysis. Commonly, cell counts are less than 50 
cells/mm3 in which neutrophils and eosinophils may 
be present.9 Generally, protein content is increased, 
IgG index is normal, and oligoclonal bands are 
usually absent.21
Serum identification of IgG-NMO has an 
important role in diagnostic workup. Nowadays 
there are several laboratory assays based on 
indirect immunofluorescence. The first and more 
widespread laboratory technique uses mouse brain 
tissues as substrate and shows a sensitivity ranging 
from 55% to 73% and specificity from 90% to 100%. 
Albeit not commercially available and using human 
AQP4-transfected cells as substrate, this test has 
73–91% of sensitivity and 100% of specificity for 
NMO.1,12
Considering the immunopathogenesis 
of NMO, since very early the demyelination of 
optic nerve and spinal cord were observed along 
with polymorphonuclear infiltrates. In 1949, it 
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(chimeric murine/human monoclonal anti-CD20) 
has been used showing a decrease in the relapse 
rate and improvement in neurological disability.32
Using neatly clinical criteria as stated by 
O’Riordan et al.9 in 1996, NMO was suspected in 
our patient. When MRI had been done, the 1999 
Wingerchuck et al.10 criteria were obeyed. The 
longitudinally and extensive spinal cord and brain 
lesions at MRI studies were all concordant with 
literature data. Taking into account the low sensitivity 
of IgG-NMO commercially available, a negative 
result did not exclude this diagnosis. Taking in 
account the severity of clinical presentation, and 
bearing in mind the massive inflammatory infiltration 
pathological process involved in this entity, which 
can lead to tissue destruction (cavitation), an 
early immunosuppressant therapy was added to 
corticosteroid and thereafter complemented by 
intravenous immunoglobulin.
CONCLUSION
In a secondary health setting, NMO 
diagnosis is a challenging one because MRI and 
IgG-NMO reactions are not easily available. These 
important subsidiary exams have to be done at 
tertiary or private hospitals and they take time. In 
severe neurological involvement, this delay can be 
life threatening. In addition, therapeutic options as 
plasma exchange and intravenous immunoglobulin 
are not easily available. After a fast exclusion 
of infectious diseases, we assume that prompt 
immune therapeutic intervention is fundamental for 
achieving more favorable outcomes.
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